ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)

Circulation

Volumn 108, Issue 15, 2003, Pages 1871-1909

  Blomström Lundqvist, Carina ^a   Scheinman, Melvin M ^a   Aliot, Etienne M ^a   Alpert, Joseph S ^a   Calkins, Hugh ^a   Camm, A John ^a   Campbell, W Barton ^a   Haines, David E ^a   Kuck, Karl H ^a   Lerman, Bruce B ^a   Miller, D Douglas ^a   Shaeffer Jr , Charlie Willard ^a   Stevenson, William G ^a   Tomaselli, Gordon F ^a   Antman, Elliott M ^a   Smith Jr , Sidney C ^a   Faxon, David P ^a   Fuster, Valentin ^a   Gibbons, Raymond J ^a   Gregoratos, Gabriel ^a   Hiratzka, Loren F ^a   Hunt, Sharon Ann ^a   Jacobs, Alice K ^a   Russell Jr , Richard O ^a   Priori, Silvia G ^a   Blanc, Jean Jacques ^a   Budaj, Andzrej ^a   Burgos, Enrique Fernandez ^a   Cowie, Martin ^a   Deckers, Jaap Willem ^a   Garcia, Maria Angeles Alonso ^a   Klein, Werner W ^a   Lekakis, John ^a   Lindahl, Bertil ^a   Mazzotta, Gianfranco ^a   Morais, João Carlos Araujo ^a   Oto, Ali ^a   Smiseth, Otto ^a   Trappe, Hans Joachim ^a   more..

^a NONE

Author keywords

Ablation; ACC AHA ESC Practice Guidelines; Arrhythmia; Drugs; Tachycardia

Indexed keywords

ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBIMAZOLE; DIGITALIS; DIGOXIN; DILTIAZEM; DIPYRIDAMOLE; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; PROPRANOLOL; PROPYLTHIOURACIL; QUINIDINE; SOTALOL; VERAPAMIL;

ARRHYTHMOGENESIS; CARDIOVERSION; CATHETER ABLATION; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOTENSION; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; SINUS BRADYCARDIA; THROMBOCYTOPENIA; VAGUS NERVE STIMULATION; VESTIBULOCOCHLEAR NERVE DISEASE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CASE MANAGEMENT; CATHETER ABLATION; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; INFANT; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 2442580222     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000091380.04100.84     Document Type: Review

References (234)

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104: 2118-2150.
2. Baine WB, Yu W, Weis KA. Trends and outcomes in the hospitalization of older Americans for cardiac conduction disorders or arrhythmias, 1991-1998. J Am Geriatr Soc. 2001;49:763-770.
3. Orejarena LA, Vidaillet H, Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998; 31:150-157.
4. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36: 2242-2246.
5. Kwong KF, Schuessler RB, Green KG, et al. Differential expression of gap junction proteins in the canine sinus node. Circ Res. 1998;82: 604-612.
6. Wu J, Schuessler RB, Rodefeld MD, et al. Morphological and membrane characteristics of spider and spindle cells isolated from rabbit sinus node. Am J Physiol Heart Circ Physiol. 2001;280:H1232-H1240.
7. Boyett MR, Honjo H, Yamamoto M, et al. Downward gradient in action potential duration along conduction path in and around the sinoatrial node. Am J Physiol. 1999;276:H686-H698.
8. Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol. 1981;314:445-456.
9. Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia. Nature. 1981;294:582-584.
10. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol. 1998;32:205-210.
11. Wu EB, Chia HM, Gill JS. Reversible cardiomyopathy after radiofrequency ablation of lateral free-wall pathway-mediated incessant supraventricular tachycardia. Pacing Clin Electrophysiol. 2000;23: 1308-1310.
12. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations, a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Circulation. 1999;100:886-893.
13. Seidl K, Rameken M, Breunung S, et al. Diagnostic assessment of recurrent unexplained syncope with a new subcutaneously implantable loop recorder. Reveal-Investigators. Europace. 2000;2:256-262.
14. Lee KL, Chun HM, Liem LB, et al. Effect of adenosine and verapamil in catecholamine-induced accelerated atrioventricular junctional rhythm: insights into the underlying mechanism. Pacing Clin Electrophysiol. 1999;22:866-870.
15. Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation. 1999;99:1034-1040.
16. Advanced cardiovascular life support: Introduction to ACLS 2000: overview of recommended changes in ACLS from the Guidelines 2000 Conference. [abstr]. Circulation. 2000;102:I86-I89.
17. Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med. 1991;20:717-721.
18. Rankin AC, Brooks R, Ruskin JN, et al. Adenosine and the treatment of supraventricular tachycardia. Am J Med. 1992;92:655-664.
19. Waxman HL, Myerburg RJ, Appel R, et al. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med. 1981;94:1-6.
20. Amsterdam EA, Kulcyski J, Ridgeway MG. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol. 1991;31:714-718.
21. Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents. J Clin Pharmacol. 1988;31: 714-718,
22. Holt P, Crick JC, Davies DW, et al. Intravenous amiodarone in the acute termination of supraventricular arrhythmias. Int J Cardiol. 1985;8: 67-79.
23. Hohnloser SH, Zabel M. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol. 1992; 70:3A-9A.
24. Glatter KA, Dorostkar PC, Yang Y, et al. Electrophysiological effects of ibutilide in patients with accessory pathways. Circulation. 2001;104: 1933-1939.
25. Gorgels AP, van den DA, Hofs A et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol. 1996;78:43-46.
26. Manz M, Mletzko R, Jung W, et al. Electrophysiological and haemodynamic effects of lidocaine and ajmaline in the management of sustained ventricular tachycardia. Eur Heart J. 1992;13:1123-1128.
27. Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet. 1994;344:18-23.
28. Part 1: Introduction to the International Guidelines 2000 for CPR and ECC: a consensus on science. Circulation. 2000;102:I1-I11.
29. Boineau JP, Schuessler RB, Hackel DB, et al. Widespread distribution and rate differentiation of the atrial pacemaker complex. Am J Physiol. 1980;239:H406-H415.
30. Scheinman MM, Levine JH, Cannom DS, et al., for the Intravenous Amiodarone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation. 1995;92:3264-3272.
31. Sharma AD, Klein GJ, Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med. 1990;88:337-343.
32. Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol. 1987;59: 1107-1110.
33. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627-633.
34. Steinherz L, Yalahom J. Cardiac toxicity. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. Philadelphia, Pa: Lippincott Williams and Wilkins. 2001:2904-2921.
35. Olgin J, Zipes D. Specific arrhythmias: diagnosis and treatment. In: Braunwald E, Zipes D, eds. Heart disease: a textbook of cardiovascular medicine. Libby P. Philadelphia, Pa: Saunders. 2001:815-889.
36. Asnis GM, Hameedi FA, Goddard AW, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001;103:1-14.
37. Stein DJ, Stein MB, Goodwin W, et al. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology (Berl). 2001;158: 267-272.
38. van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 15(suppl 2):S15-S23, 2000.
39. Schomig A, Kastrati A, Dirschinger J, et al. for the Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 2000;343:385-391.
40. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. Lancet. 1998;351:1180-1181.
41. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
42. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501-509.
43. Cossu SF, Steinberg JS. Supraventricular tachyarrhythmias involving the sinus node: clinical and electrophysiologic characteristics. Prog Cardiovasc Dis. 1998;41:51-63.
44. Sato T, Mitamura H, Murata M, et al. Electrophysiologic findings of a patient with inappropriate sinus tachycardia cured by selective radiofrequency catheter ablation. J Electrocardiol. 2000;33:381-386.
45. Mischke K, Stellbfink C, Hanrath P. Evidence of sinoatrial block as a curative mechanism in radiofrequency current ablation of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol. 2001;12:264-267.
46. Man KC, Knight B, Tse HF, et al. Radiofrequency catheter ablation of inappropriate sinus tachycardia guided by activation mapping. J Am Coll Cardiol. 2000;35:451-457.
47. Lee RJ, Kalman JM, Fitzpatrick AP, et al. Radiofrequency catheter modification of the sinus node for "inappropriate" sinus tachycardia. Circulation. 1995;92:2919-2928.
48. Yee R, Guiraudon GM, Gardner MJ, et al. Refractory paroxysmal sinus tachycardia: management by subtotal right atrial exclusion. J Am Coll Cardiol. 1984;3:400-404.
49. Esmailzadeh B, Bernat R, Winkler K, et al. Surgical excision of the sinus node in a patient with inappropriate sinus tachycardia. J Thorac Cardiovasc Surg. 1997;114:861-864.
50. de Paola AA, Horowitz LN, Vattimo AC, et al. Sinus node artery occlusion for treatment of chronic nonparoxysmal sinus tachycardia. Am J Cardiol. 1992;70:128-130.
51. Jayaprakash S, Sparks PB, Vohra J. Inappropriate sinus tachycardia (IST): management by radiofrequency modification of sinus node. Aust N Z J Med. 1997;27:391-397.
52. Goya M, lesaka Y, Takahashi A, et al. Radiofrequency catheter ablation for sinoatrial node re-entrant tachycardia: electrophysiologic features of ablation sites. Jpn Circ J. 1999;63:177-183.
53. Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am Heart J. 2001;142:93-98.
54. Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37:548-553.
55. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol. 2000;23:1020-1028.
56. Clague JR, Dagres N, Kottkamp H, et al. Targeting the slow pathway for atrioventricular nodal re-entrant tachycardia: initial results and long-term follow-up in 379 consecutive patients. Eur Heart J. 2001;22: 82-88.
57. Calkins H, Yong P, Miller JM, et al., for the Atakr Multicenter Investigators Group. Catheter ablation of accessory pathways, atrioventricular nodal re-entrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. Circulation. 1999;99: 262-270.
58. Akhtar M, Jazayeri MR, Sra J, et al. Atrioventricular nodal re-entry: clinical, electrophysiological, and therapeutic considerations. Circulation. 1993;88:282-295.
59. Mauritson DR, Winniford MD, Walker WS, et al. Oral verapamil for paroxysmal supraventricular tachycardia: a long-term, double-blind randomized trial. Ann Intern Med. 1982;96:409-412.
60. Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol. 1984;54:1138-1139.
61. Anderson JL, Platt ML, Guarnieri T, et al., for the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. Am J Cardiol. 1994;74:578-584.
62. Pritchett EL, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539-544.
63. Wanless RS, Anderson K, Joy M, et al. Multicenter comparative study of the efficacy and safety of sotalol in the prophylactic treatment of patients with paroxysmal supraventricular tachyarrhythmias. Am Heart J. 1997;133:441-446.
64. Henthorn RW, Waldo AL, Anderson JL, et al., for the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation. 1991;83:119-125.
65. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 1995;92: 2550-2557.
66. Gambhir DS, Bhargava M, Nair M, et al. Comparison of electrophysiologic effects and efficacy of single-dose intravenous and long-term oral amiodarone therapy in patients with AV nodal re-entrant tachycardia. Indian Heart J. 1996;48:133-137.
67. Bogun F, Knight B, Weiss R, et al. Slow pathway ablation in patients with documented but noninducible paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 1996;28:1000-1004.
68. Hamdan MH, Dorostkar P, Scheinman M. Junctional tachycardia and junctional rhythm. In: Zipes D, Jalife J, eds. Cardiac electrophysiology: from cell to bedside. Philadelphia, PA: WB Saunders, 2000:482-488.
69. Kuck KH, Kunze KP, Schluter M, et al. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am J Cardiol. 1988; 62:37L-44L.
70. Paul T, Reimer A, Janousek J, et al. Efficacy and safety of propafenone in congenital junctional ectopic tachycardia. J Am Coll Cardiol. 1992; 20:911-914.
71. Maragnes P, Fournier A, Davignon A. Usefulness of oral sotalol for the treatment of junctional ectopic tachycardia. Int J Cardiol. 1992;35: 165-167.
72. Fidell J, Do-Ngoc D, Attuel P, et al. L'amiodarone dans le traitement des troubles du rythme cardiaque de l'enfant. Arch Mal Coeur Vaiss. 1973; 2:198-204.
73. Villain E, Vetter VL, Garcia JM, et al. Evolving concepts in the management of congenital junctional ectopic tachycardia: a multicenter study. Circulation. 1990;81:1544-1549.
74. Ehlert FA, Goldberger JJ, Deal BJ, et al. Successful radiofrequency energy ablation of automatic junctional tachycardia preserving normal atrioventricular nodal conduction. Pacing Clin Electrophysiol. 1993;16: 54-61.
75. Hamdan M, Van Hare GF, Fisher W, et al. Selective catheter ablation of the tachycardia focus in patients with nonre-entrant junctional tachycardia. Am J Cardiol. 1996;78:1292-1297.
76. Scheinman MM, Gonzalez RP, Cooper MW, et al. Clinical and electrophysiologic features and role of catheter ablation techniques in adult patients with automatic atrioventricular junctional tachycardia. Am J Cardiol. 1994;74:565-572.
77. Castellanos A, Sung RJ, Myerburg RJ. His bundle electrocardiography in digitalis-induced "atrioventricular junctional" Wenckebach periods with irregular H-H intervals. Am J Cardiol. 1979;43:653-656.
78. Storstein O, Hansteen V, Hatle L, et al. Studies on digitalis: XIII: a prospective study of 649 patients on maintenance treatment with digitoxin. Am Heart J. 1977;93:434-443.
79. Fisch C. Myocardial infarction: accelerated junctional rhythm. J Indiana State Med Assoc. 1970;63:350.
80. Breslow MJ, Evers AS, Lebowitz P. Successful treatment of accelerated junctional rhythm with propranolol: possible role of sympathetic stimulation in the genesis of this rhythm disturbance. Anesthesiology. 1985; 62:180-182.
81. Dagres N, Clague JR, Lottkamp H, et al. Impact of radiofrequency catheter ablation of accessory pathways on the frequency of atrial fibrillation during long-term follow-up; high recurrence rate of atrial fibrillation in patients older than 50 years of age. Eur Heart J. 2001; 22:423-427.
82. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344:1823-1831.
83. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J. 2001;22:1374-1450.
84. Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol. 2003;41:239-244.
85. Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med. 1991;324:1605-1611.
86. Manolis AS, Katsaros C, Cokkinos DV. Electrophysiological and electropharmacologic studies in pre-excitation syndromes: results with propafenone therapy and isoproterenol infusion testing. Eur Heart J. 1992;13:1489-1495.
87. Zipes DP, DiMarco JP, Gillette PC, et al. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedure: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 1995;26:555-573.
88. Janousek J, Paul T, Reimer A, et al. Usefulness of propafenone for supraventricular arrhythmias in infants and children. Am J Cardiol. 1993;72:294-300.
89. Musto B, D'Onofrio A, Cavallaro C, et al. Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia. Circulation. 1988;78:863-869.
90. Vignati G, Mauri L, Figini A. The use of propafenone in the treatment of tachyarrhythmias in children. Eur Heart J. 1993;14:546-550.
91. Vassiliadis I, Papoutsakis P, Kallikazaros I, et al. Propafenone in the prevention of nonventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. Int J Cardiol. 1990;27:63-70.
92. Helmy I, Scheinman MM, Herre JM, et al. Electrophysiologic effects of isoproterenol in patients with atrioventricular re-entrant tachycardia treated with flecainide. J Am Coll Cardiol. 1990;16:1649-1655.
93. Kim SS, Lal R, Ruffy R. Treatment of paroxysmal re-entrant supraventricular tachycardia with flecainide acetate. Am J Cardiol. 1986;58: 80-85.
94. Cockrell JL, Scheinman MM, Titus C, et al. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia. Ann Intern Med. 1991;114:189-194.
95. Hoff PI, Tronstad A, Oie B, et al. Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia. Am J Cardiol. 1988;62:585-589.
96. Wiseman MN, Elstob JE, Camm AJ, et al. A study of the use of flecainide acetate in the long-term management of cardiac arrhythmias. Pacing Clin Electrophysiol. 1990;13:767-775.
97. Benditt DG, Dunnigan A, Buetikofer J, et al. Flecainide acetate for long-term prevention of paroxysmal supraventricular tachyarrhythmias. Circulation. 1991;83:345-349.
98. Pritchett EL, DaTorre SD, Platt ML, et al., for the Flecainide Supraventricular Tachycardia Study Group. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. J Am Coll Cardiol. 1991;17:297-303.
99. Manolis AS, Estes NA, III. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1989;64:194-198.
100. Kunze KP, Schluter M, Kuck KH. Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation. 1987;75:1050-1057.
101. Mason JW. Amiodarone. N Engl J Med. 1987;316:455-466.
102. Rosenbaum MB, Chiale PA, Ryba D, et al. Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol. 1974;34:215-223.
103. Wellens HJ, Lie KI, Bar FW, et al. Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1976;38:189-194.
104. Kappenberger LJ, Fromer MA, Steinbrunn W, et al. Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation. Am J Cardiol. 1984;54:330-335.
105. Lai WT, Voon WC, Yen HW, et al. Comparison of the electrophysiologic effects of oral sustained-release and intravenous verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol. 1993;71:405-408.
106. Calkins H, Sousa J, el Atassi R, et al. Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test. N Engl J Med. 1991;324:1612-1618.
107. Kuck KH, Schluter M, Geiger M, et al. Radiofrequency current catheter ablation of accessory atrioventricular pathways. Lancet. 1991;337: 1557-1561.
108. Calkins H, Langberg J, Sousa J, et al. Radiofrequency catheter ablation of accessory atrioventricular connections in 250 patients: abbreviated therapeutic approach to Wolff-Parkinson-White syndrome. Circulation. 1992;85:1337-1346.
109. Lesh MD, Van Hare GF, Scheinman MM, et al. Comparison of the retrograde and transseptal methods for ablation of left free wall accessory pathways. J Am Coll Cardiol. 1993;22:542-549.
110. Scheinman MM. NASPE survey on catheter ablation. Pacing Clin Electrophysiol. 1995;18:1474-1478.
111. Hindricks G for the Multicentre European Radiofrequency Survey (MERFS) investigators of the Working Group on Arrhythmias of the European Society of Cardiology. The Multicentre European Radiofrequency Survey (MERFS): complications of radiofrequency catheter ablation of arrhythmias. Eur Heart J. 1993;14:1644-1653.
112. Yeh SJ, Lin FC, Chou YY, et al. Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem and propranolol. Circulation. 1985;71:104-109.
113. Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a statement from a joint expert group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001;22:1162-1182.
114. Steinbeck G, Hoffmann E. 'True' atrial tachycardia. Eur Heart J. 1998; 19(suppl E):E10-2, E48-9.:E10-E19.
115. Poutiainen AM, Koistinen MJ, Airaksinen KE, et al. Prevalence and natural course of ectopic atrial tachycardia. Eur Heart J. 1999;20: 694-700.
116. Wren C. Incessant tachycardias. Eur Heart J. 1998;19(suppl E):E32-6, E54-9.
117. Lee SH, Tai CT, Lin WS, et al. Predicting the arrhythmogenic foci of atrial fibrillation before atrial transseptal procedure: implication for catheter ablation. J Cardiovasc Electrophysiol. 2000;11:750-757.
118. SippensGroenewegen A, Peeters HA, Jessurun ER, et al. Body surface mapping during pacing at multiple sites in the human atrium: P-wave morphology of ectopic right atrial activation. Circulation. 1998;97: 369-380.
119. Kalman JM, Olgin JE, Karch MR, et al. "Cristal tachycardias": origin of right atrial tachycardias from the crista terminalis identified by intracardiac echocardiography. J Am Coll Cardiol. 1998;31:451-459.
120. Tada H, Nogami A, Naito S, et al. Simple electrocardiographic criteria for identifying the site of origin of focal right atrial tachycardia. Pacing Clin Electrophysiol. 1998;21:2431-2439.
121. Hoffmann E, Reithmann C, Nimmermann P, et al. Clinical experience with electroanatomic mapping of ectopic atrial tachycardia. Pacing Clin Electrophysiol. 2002;25:49-56.
122. Lai LP, Lin JL, Chen TF, et al. Clinical, electrophysiological characteristics, and radiofrequency catheter ablation of atrial tachycardia near the apex of Koch's triangle. Pacing Clin Electrophysiol. 1998;21:367-374.
123. Markowitz SM, Stein KM, Mittal S, et al. Differential effects of adenosine on focal and macrore-entrant atrial tachycardia. J Cardiovasc Electrophysiol. 1999;10:489-502.
124. Hsieh MH, Chen SA. Catheter ablation of focal AT. In: Zipes DP, Haissaguerre M, eds. Catheter ablation of arrhythmias. Armonk, NY: Futura Publishing Co., Inc., 2002:185-204.
125. Chen SA, Tai CT, Chiang CE, et al. Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic characteristics and prediction of successful radiofrequency ablation. J Cardiovasc Electrophysiol. 1998; 9:355-365.
126. Schmitt C, Zrenner B, Schneider M, et al. Clinical experience with a novel multielectrode basket catheter in right atrial tachycardias. Circulation. 1999;99:2414-2422.
127. Natale A, Breeding L, Tomassoni G, et al. Ablation of right and left ectopic atrial tachycardias using a three-dimensional nonfluoroscopic mapping system. Am J Cardiol. 1998;82:989-992.
128. Weiss C, Willems S, Cappato R, et al. High frequency current ablation of ectopic atrial tachycardia: different mapping strategies for localization of right- and left-sided origin. Herz. 1998;23:269-279.
129. Anguera I, Brugada J, Roba M, et al. Outcomes after radiofrequency catheter ablation of atrial tachycardia. Am J Cardiol. 2001;87:886-890.
130. Engelstein ED, Lippman N, Stein KM, et al. Mechanism-specific effects of adenosine on atrial tachycardia. Circulation. 1994;89:2645-2654.
131. Harrison DA, Siu SC, Hussain F, et al. Sustained atrial arrhythmias in adults late after repair of tetralogy of fallot. Am J Cardiol. 2001;87: 584-588.
132. Stock JP. Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol. 1966;18:444-449.
133. Kunze KP, Kuck KH, Schluter M, et a;. Effect of encainide and flecainide on chronic ectopic atrial tachycardia. J Am Coll Cardiol. 1986; 7:1121-1126.
134. Berns E, Rinkenberger RL, Jeang MK, et al. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol. 1987;59:1337-1341.
135. Coumel P, Leclercq JF, Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias. Am J Cardiol. 1984;54:60D-66D.
136. Lesh MD, Kalman JM, Olgin JE. New approaches to treatment of atrial flutter and tachycardia. J Cardiovasc Electrophysiol. 1996;7:368-381.
137. Beaufort-Krol GC, Bink-Boelkens MT. Sotalol for atrial tachycardias after surgery for congenital heart disease. Pacing Clin Electrophysiol. 1997;20:2125-2129.
138. Carrasco HA, Vicuna AV, Molina C, et al. Effect of low oral doses of disopyramide and amiodarone on ventricular and atrial arrhythmias of chagasic patients with advanced myocardial damage. Int J Cardiol. 1985;9:425-438.
139. Kopelman HA, Horowitz LN. Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. Prog Cardiovasc Dis. 1989;31:355-366.
140. Prager NA, Cox JL, Lindsay BD, et al. Long-term effectiveness of surgical treatment of ectopic atrial tachycardia. J Am Coll Cardiol. 1993;22:85-92.
141. Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients: electrophysiological characteristics, pharmacologic response, possible mechanisms, and effects of radiofrequency ablation. Circulation. 1994;90:1262-1278.
142. Creamer JE, Nathan AW, Camm AJ, Successful treatment of atrial tachycardias with flecainide acetate. Br Heart J. 1985;53:164-166.
143. Pool PE, Quart BD. Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide. Am J Cardiol. 1988; 62:60L-62L.
144. Cheng J, Scheinman MM. Acceleration of typical atrial flutter due to double-wave re-entry induced by programmed electrical stimulation. Circulation. 1998;97:1589-1596.
145. Cheng J, Cabeen WR Jr, Scheinman MM. Right atrial flutter due to lower loop re-entry; mechanism and anatomic substrates. Circulation. 1999;99:1700-1705.
146. Yang Y, Cheng J, Bochoeyer A, et al. Atypical right atrial flutter patterns. Circulation. 2001;103:3092-3098.
147. Friedman PA, Luria D, Fenton AM, et al. Global right atrial mapping of human atrial flutter: the presence of posteromedial (sinus venosa region) functional block and double potentials: a study in biplane fluoroscopy and intracardiac echocardiography. Circulation. 2000;101:1568-1577.
148. Li W, Somerville J. Atrial flutter in grown-up congenital heart (GUCH) patients: clinical characteristics of affected population. Int J Cardiol. 2000;75:129-137.
149. Puley G, Siu S, Connelly M, et al. Arrhythmia and survival in patients > 18 years of age after the mustard procedure for complete transposition of the great arteries. Am J Cardiol. 1999;83:1080-1084.
150. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter of fibrillation. J Am Coll Cardiol. 1998; 31:1414-1419.
151. Vos MA, Golitsyn SR, Stangl K, et al., for the Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over DL-sotalol in convertiug atrial flutter and atrial fibrillation. Heart. 1998; 79:568-575.
152. Doni F, Manfredi M, Piemonti C, et al. New onset atrial flutter termination by overdrive transoesophageal pacing: effects of different protocols of stimulation. Europace. 2000;2:292-296.
153. Rostas L, Antal K, Putorek Z, Transesophageal pacemaker therapy in atrial flutter after procainamide pretreatment. Am J Ther. 1999;6: 237-240.
154. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385-2390.
155. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104:292-296.
156. Benditt DG, Williams JH, Jin J, et al., for the d, 1-Sotalol Atrial Fibrillation/Flutter Study Group. Maintenance of sinus rhythm with oral d, 1-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. Am J Cardiol. 1999;84:270-277.
157. Dunn MI. Thrombolism with atrial flutter. Am J Cardiol. 1998;82:638.
158. Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol. 1998;82:580-583.
159. Weiss R, Marcovitz P, Knight BP, et al. Acute changes in spontaneous echo contrast and atrial function after cardioversion of persistent atrial flutter. Am J Cardiol. 1998;82:1052-1055.
160. Sparks PB, Jayaprakash S, Vohra JK, et al. Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol. 1998;32:468-475.
161. Lip GY, Kamath S. Thromboprophylaxis for atrial flutter. Eur Heart J. 2001;22:984-987.
162. Willems S, Weiss C, Ventura R, et al. Catheter ablation of atrial flutter guided by electroanatomic mapping (CARTO): a randomized comparison to the conventional approach. J Cardiovasc Electrophysiol. 2000;11:1223-1230.
163. Kottkamp H, Hugl B, Krauss B, et al. Electromagnetic versus fluoroscopic mapping of the inferior isthmus for ablation of typical atrial flutter: a prospective randomized study. Circulation. 2000;102: 2082-2086.
164. Natale A, Newby KH, Pisano E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35: 1898-1904.
165. Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol. 1999;83:710-713.
166. Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenonc: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction, J Cardiovasc Electrophysiol. 1999;10:1180-1187.
167. Nabar A, Rodriguez LM, Timmermans C, et al. Radiofrequency ablation of "class IC atrial flutter" in patients with resistant atrial fibriltation. Am J Cardiol. 1999;83:785-787, A10.
168. Reithmann C, Hoffmann E, Spitzlberger G, et al. Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation. Eur Heart J. 2000;21:565-572.
169. Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:462-469.
170. VanderLugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation. 1999;100:369-375.
171. Delle KG, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001;29:1149-1153.
172. Nakagawa H, Shah N, Matsudaira K, et al. Characterization of re-entrant circuit in macrore-entrant right atrial tachycardia after surgical repair of congenital heart disease: isolated channels between scars allow "focal" ablation. Circulation. 2001;103:699-709.
173. Shah D, Jais P, Takahashi A, et al. Dual-loop intra-atrial re-entry in humans. Circulation. 2000;101:631-639.
174. Triedman JK, Alexander ME, Berul CI, et al. Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial re-entrant tachycardia. Circulation. 2001;103: 2060-2065.
175. Triedman JK, Saul JP, Weindling SN, et al. Radiofrequency ablation of intra-atrial re-entrant tachycardia after surgical palliation of congenital heart disease. Circulation. 1995;91:707-714.
176. Akar JG, Kok LC, Haines DE, et al. Coexistence of type I atrial flutter and intra-atrial re-entrant tachycardia in patients with surgically corrected congenital heart disease. J Am Coll Cardiol. 2001;38:377-384.
177. Chan DP, Van Hare GF, Mackall JA, et al. Importance of atrial flutter isthmus in postoperative intra-atrial re-entrant tachycardia. Circulation. 2000;102:1283-1289.
178. Delacretaz E, Ganz LI, Soejima K, et al. Multi atrial macro-re-entry circuits in adults with repaired congenital heart disease: entrainment mapping combined with three-dimensional electroanatomic mapping. J Am Coll Cardiol. 2001;37:1665-1676.
179. Duru F, Hindricks G, Kottkamp H. Atypical left atrial flutter after intraoperative radiofrequency ablation of chronic atrial fibrillation: successful ablation using three-dimensional electroanatomic mapping. J Caidiovasc Electrophysiol. 2001;12:602-605.
180. Thomas SP, Nunn GR, Nicholson IA, et al. Mechanism, localization and cure of atrial arrhythmias occurring after a new intraoperative endocardial radiofrequency ablation procedure for atrial fibrillation. J Am Coll Cardiol. 2000;35:442-450.
181. Hebe J, Hansen P, Ouyang F, et al. Radiofrequency catheter ablation of tachycardia in patients with congenital heart disease. Pediatr Cardiol. 2000;21:557-575.
182. Kall JG, Rubenstein DS, Kopp DE, et al. Atypical atrial flutter originating in the right atrial free wall. Circulation. 2000;101:270-279.
183. Molenschot M, Ramanna H, Hoorntje T, et al. Catheter ablation of incisional atrial tachycardia using a novel mapping system: LocaLisa. Pacing Clin Electrophysiol. 2001;24:1616-1622.
184. Jais P, Shah DC, Haissaguerre M, et al. Mapping and ablation of left atrial flutters. Circulation. 2000;101:2928-2934.
185. Tai CT, Lin YK, Chen SA. Atypical atrial flutter involving the isthmus between the right pulmonary veins and fossa ovalis. Pacing Clin Electrophysiol. 2001;24:384-387.
186. Tucker KJ, Wilson C. A comparison of transoesophageal atrial pacing and direct current cardioversion for the termination of atrial flutter: a prospective, randomised clinical trial. Br Heart J. 1993;69:530-535.
187. Doni F, Della BP, Kheir A, et al. Atrial flutter termination by overdrive transesophageal pacing and the facilitating effect of oral propafenone. Am J Cardiol. 1995;76:1243-1246.
188. Doni F, Staffiere E, Manfredi M, et al. Type II atrial flutter interruption with transesophageal pacing: use of propafenone and possible change of the substrate. Pacing Clin Electrophysiol. 1996;19:1958-1961.
189. Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J. 1967; 29:469-489.
190. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722-1727.
191. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil. Am J Cardiol. 1992;70:56A-60A.
192. Stambler BS, Wood MA, Ellenbogen KA, et al., for the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94:1613-1621.
193. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996;28:130-136.
194. Sung RJ, Tan HL, Karagounis L, et al., for the Sotalol Multicenter Study Group. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J. 1995;129:739-748.
195. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study. Eur Heart J. 1995;16:521-528.
196. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. Ann Emerg Med. 1997;29:135-140.
197. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63:925-929.
198. Goldenberg IF, Lewis WR, Dias VC, et al. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure. Am J Cardiol. 1994;74:884-889.
199. Chen SA, Chiang CE, Wu TJ, et al. Radiofrequency catheter ablation of common atrial flutter: comparison of electrophysiologically guided focal ablation technique and linear ablation technique. J Am Coll Cardiol. 1996;27:860-868.
200. Naccarelli GV, Dorian P, Hohnloser SH, et al, for the Flecainide Multicenter Atrial Fibrillation Study Group. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol. 1996;77:53A-59A.
201. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation), developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001;22: 1852-1923.
202. Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999;20:85-94.
203. Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation. 2001;104:893-897.
204. Lydakis C, Lip GY, Beevers M, et al. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12: 541-547.
205. Simpson JM, Sharland GK. Fetal tachycardias: management and outcome of 127 consecutive cases. Heart. 1998;79:576-581.
206. Bartalena L, Bogazzi F, Braverman LE, et al. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest. 2001;24:116-130.
207. Gatzoulis MA, Freeman MA, Siu SC, et al. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med. 1999; 340:839-846.
208. Attie F, Rosas M, Granados N, et al. Surgical treatment for secundum atrial septal defects in patients >40 years old: a randomized clinical trial. J Am Coll Cardiol. 2001;38:2035-2042.
209. Donti A, Bonvicini M, Placci A, et al. Surgical treatment of secundum atrial septal defect in patients older than 50 years. Ital Heart J. 2001;2: 428-432.
210. Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with congenital heart disease. J Am Coll Cardiol. 2002;39:1827-1835.
211. Gatzoulis MA, Walters J, McLaughlin PR, et al. Late arrhythmia in adults with the mustard procedure for transposition of great arteries: a surrogate marker for right ventricular dysfunction? Heart. 2000;84: 409-415.
212. Sarkar D, Bull C, Yates R, et al. Comparison of long-term outcomes of atrial repair of simple transposition with implications for a late arterial switch strategy. Circulation. 1999;100:11176-11181.
213. Li W, Somerville J, Gibson DG, et al. Disturbed atrioventricular electromechanical function long after Mustard operation for transposition of great arteries: a potential contributing factor to atrial flutter. J Am Soc Echocardiogr. 2001;14:1088-1093.
214. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975-981.
215. Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation. 2001;103:2489-2494.
216. Natterson PD, et al. Electrophysiologic abnormalities: unoperated occurrence and postoperative residua and sequelae. In: Perloff J, Child JS, eds. Congenital heart disease in adults. Philadelphia, PA: WB Saunders, 1998:316-339.
217. Hebe J. Ebstein's anomaly in adults arrhythmias: diagnosis and therapeutic approach. Thorac Cardiovasc Surg. 2000;48:214-219.
218. Ho SY, Goltz D, McCarthy K, et al. The atrioventricular junctions in Ebstein malformation. Heart. 2000;83:444-449.
219. Attie F, Rosas M, Rijlaarsdam M, et al. The adult patient with Ebstein anomaly: outcome in 72 unoperated patients. Medicine (Baltimore). 2000;79:27-36.
220. Huang CJ, Chiu IS, Lin FY, et al. Role of electrophysiological studies and arrhythmia intervention in repairing Ebstein's anomaly. Thorac Cardiovasc Surg. 2000;48:347-350.
221. Reich JD, Auld D, Hulse E, et al., for the Pediatric Electrophysiology Society. The Pediatric Radiofrequency Ablation Registry's experience with Ebstein's anomaly. J Cardiovasc Electrophysiol. 1998;9: 1370-1377.
222. Gatzoulis MA, Munk MD, Williams WG, et al. Definitive palliation with cavopulmonary or aortopulmonary shunts for adults with single ventricle physiology. Heart. 2000;83:51-57.
223. Ghai A, Harris L, Harrison DA, et al. Outcomes of late atrial tachyarrhythmias in adults after the Fontan operation. J Am Coll Cardiol. 2001;37:585-592.
224. Lesh MD, Van Hare GF, Epstein LM, et al. Radiofrequency catheter ablation of atrial arrhythmias: results and mechanisms. Circulation. 1994;89:1074-1089.
225. Triedman JK, Jenkins KJ, Colan SD, et al. Intra-atrial re-entrant tachycardia after palliation of congenital heart disease: characterization of multiple macrore-entrant circuits using fluoroscopically based three-dimensional endocardial mapping. J Cardiovasc Electrophysiol. 1997; 8:259-270.
226. Misaki T, Watanabe G, Iwa T, et al. Surgical treatment of patients with Wolff-Parkinson-White syndrome and associated Ebstein's anomaly. J Thorac Cardiovasc Surg. 1995;110:1702-1707.
227. Bubien RS, Knotts-Dolson SM, Plumb VJ, et al. Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias. Circulation. 1996; 94:1585-1591.
228. Lau CP, Tai YT, Lee PW. The effects of radiofrequency ablation versus medical therapy on the quality-of-life and exercise capacity in patients with accessory pathway-mediated supraventricular tachycardia: a treatment comparison study. Pacing Clin Electrophysiol. 1995;18: 424-432.
229. Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol. 1998;82:589-593.
230. Cheng CH, Sanders GD, Hlatky MA, et al. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med. 2000;133:864-876.
231. Goldberg AS, Bathina MN, Mickelsen S, et al. Long-term outcomes on quality-of-life and health care costs in patients with supraventricular tachycardia (radiofrequency catheter ablation versus medical therapy). Am J Cardiol. 2002;89:1120-1123.
232. Anselme F, Saoudi N, Poty H, et al. Radiofrequency catheter ablation of common atrial flutter: significance of palpitations and quality-of-life evaluation in patients with proven isthmus block. Circulation. 1999;99: 534-540.
233. Lee SH, Tai CT, Yu WC, et al. Effects of radiofrequency catheter ablation on quality of life in patients with atrial flutter. Am J Cardiol. 1999;84:278-283.
234. O'Callaghan PA, Meara M, Kongsgaard E, et al. Symptomatic improvement after radiofrequency catheter ablation for typical atrial flutter. Heart. 2001;86:167-171.